Adding BTK inhibitor to the standard DLBCL chemoimmunotherapy R‐CHOP regimen in non‐GCB‐DLBCL did not improve survival202 but other combinations might prove to be more beneficial. This evidence concerns the gene BTK and diffuse large B-cell lymphoma.